Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors in adults with insufficient current treatment options and very poor prognosis. Aggressive behavior of GBM cells and their therapeutic resistance are based on complex biological features including changes in the microtubule cytoskeleton. Microtubule targeting belongs to one of the fundamental approaches to cancer treatment, and previously described overexpression of certain tubulin isoforms suggests possible benefit in the use of microtubule targeting agents, such as the repurposed compound flubendazole (FLU).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
